Publications

0
Total number of publications by D.G. (scroll down)
0
Total number of lab publications (scroll down)
Authored since 2010 by lab members ...
--- postdocs 51%
--- PhD/MD students 60.2%
--- technicians 19.4%
--- others 12.2%

2023

  1. S.A. Theuerkauf, E. Herrera-Carrillo, F. John, L.J. Zinser, M.A. Molina, V. Riechert, F.B. Thalheimer, K. Boerner, D. Grimm, P. Chlanda, B. Berkhout, and C.J. Buchholz. AAV vectors displaying bispecific DARPins enable dual-control targeted gene delivery. Biomaterials, in press.
  2. M. Thuerkauf, S. Lin, F. Oliveri, D. Grimm, R.J. Platt, and M. Ruegg. Fast, multiplexable and efficient somatic gene deletions in adult mouse skeletal muscle fibers uzsing AAV-CRISPR/Cas9. Nat. Commun., 14:6116.
  3. M. Grosch, L. Schraft, A. Chan, L. Kuechenhoff. K. Rapti, A.-M. Ferreira, J. Kornienko, S. Li, M.H. Radke, C. Kraemer, S., Claude-Muenster, E. Perlas, J. Backs, M. Gotthardt, C. Dieterich, M.M. van den Hoogenhof, D. Grimm, and L. Steinmetz. Striated muscle-specific base editing enables correction of mutations causing dilated cardiomyopathy. Nat. Commun., 14:3714.
  4. S.D.M. Velasquez, E. Gerstmann, and D. Grimm. Goody two plasmids: An optimized transient transfection system for AAV vector production. Mol. Ther. Methods Clin. Dev., 13:191-193.
  5. J. Voigt, J. Timmer, F. Pennarola, J. Christian, N. Meng, J. Blumberg, U. Schwarz, D. Grimm, and E.A. Cavalcanti-Adam. Substrate stiffness and particle properties influence cellular uptake of nanoparticles and viruses from the ventral side. Adv. Funct. Mater., in press.
  6. N. Stajkovic, Y. Liu, A. Arsic, N. Meng, H. Lyu, N. Zhang, D. Grimm, H. Lerche, and I. Nikic-Spiegel.  Direct fluoerescent labeling of NF186 and NaV1.6 in living primary neurons using bioorthogonal click chemistry. J. Cell. Sci., 136:jcs260600.
  7. J. Szumska, and D. Grimm. Boosters for Adeno-associated virus (AAV) vector (r)evolution. Cytotherapy, 25:254-260.
  8. D. Grimm, and M. Nonnenmacher. Every little bit helps : A single-residue switch in a vascular AAV enables blood-brain barrier penetration. Mol. Ther. Methods Clin. Dev., 29:364-365.
  9. J. Liu*, T. Koay*, O. Maiakovska, M. Zayas, and D. Grimm. Progress in bioengineering oy myotropic Adeno-associated viral (AAV) gene therapy vectors. Hum. Gene Ther., 34:350-364.
  10. F. Kermani, M. Mosqueira, K. Peter, E.D. Lemma, K. Rapti, D. Grimm, M. Bastmeyer, M. Laugsch, M. Hecker, and N.D. Ullrich. Membrane remodelling triggers maturation of excitation-contraction coupling in 3D-shaped human-induced pluripotent stem cell-derived cardiomyocytes. Basic Res. Cardiol., 118:13.
  11. J.H. Yang, (…), J.E. Andari, D. Grimm, (…), and D. Sinclair. Loss of epigenetic information as a cause of mammalian aging. Cell, 186:305-326.e27.

2022

  1. A. Waithaka, O. Maiakovska, D. Grimm, L.M. do Nascimento, and C. Clayton. Sequences and proteins that influence mRNA processing in Trypanosoma brucei: Evolutionary conservation of SR-domain and PTB protein functions. PLoS Negl. Trop. Dis., 16:e0010876.
  2. O. Maiakovska*, C. Baumgartl*, and D. Grimm. Determination of AAV properties by single amino acids: Go(o)d is in the details. Mol. Ther. Methods Clin. Dev., 29:93-95. *equal first authors
  3. K. Rapti, O. Maiakovska, J. Becker, J. Szumska, M. Zayas, F. Bubeck, J. Liu, E. Gerstmann, C. Krämer, E. Wiedtke, and D. Grimm. Isolation of next-generation gene therapy vectors through engineering, barcoding, and screening of Adeno-associated virus (AAV) capsid variants. J. Vis. Exp., doi:10.379164389.
  4. J.E. Andari, E. Renaud-Gabardos, W. Tulalamba, J. Weinmann, L. Mangin, Q.H. Pham, S. Hille, A. Bennett, E. Attebi, E. Bourges, C. Leborgne, N. Guerchet, J. Fakhiri, C. Krämer, E. Wiedtke, R. McKenna, L. Guianvarc’h, M. Toueille, G. Ronzitti, M. Hebben, F. Mingozzi, T. VandenDriessche, M. Agbandje-McKenna, O.J. Müller, M.K. Chuah, Ana Buj-Bello, and D. Grimm. Semirational bioengineering of AAV vectors with increased potency and specificity for systemic gene therapy of muscle disorders. Sci. Adv., 8:eabn4704.
  5. A. Rovai, B. Chung, Q. Hu, S. Hook, Q. Yuan, T. Kempf, F. Schmidt, D. Grimm, S.R. Talbot, L. Steinbrück, J. Götting, J. Bohne, S.A. Krooss, and M. Ott. In vivo adenine base editing reverts C272Y and improves iron metabolism in hemochromatosis mice. Nat. Commun., 13:5215.
  6. .M. Mann, W. Schäfer, S. Adriouch, K. Börner, D. Grimm, I. Braren, and F. Koch-Nolte. Enhanced transduction of P2X7-expressing cells with recombinant rAAV vectors. Methods Mol. Biol., 2510:129-144.
  7. J. Becker, J. Fakhiri*, and D. Grimm*. Fantastic AAV gene therapy vectors and how to find them – random diversification, rational design and machine learning. *equal corresponding and equal last authors. Pathogens, 11:756.
  8. L.J. Flitsch, K. Börner, C. Stüllein, S. Ziegler, V. Sonntag-Buck, E. Wiedtke, V. Semkova, S.W.C.A. Yeung, J. Schlee, M. Hajo, M. Mathews, B.S. Ludwig, S. Kossatz, H. Kessler, D. Grimm*, and O. Brüstle*. Identification of adeno-associated virus variants for gene transfer into human neural cell types by parallel capsid screening. *equal corresponding authors. Sci. Rep., 12:8356.
  9. A.J. Gadenstaetter, L. Schmutzler, D. Grimm, and L.D. Landegger. Intranasal application of Adeno-associated viruses: A systematic review. Transl. Res., 248:87-110.
  10. J. Becker*, N. Fischer*, and D. Grimm. Right on target: The next class of efficient, safe, and specific RNAi triggers. Mol. Ther. Nucleic Acids, 28:363-365. *equal first authors
  11. E. Melendez, D. Chondronasiou, L. Mosteiro, J.M. de Villareal, M. Fernández-Alfara, C. Lynch, D. Grimm, F.X. Real, J. Alcamí, N. Climent, F. Piertocla, and M. Serrano. Natural killer cells act as an extrinsic barrier for in vivo reprogramming. Development, 149:dev200361.
  12. A. Bauer, M. Puglisi, D. Nagl, J.A. Schick, T. Werner, A. Klingl, J.E. Andari, V. Hornung, H. Kessler, M. Götz, D. Grimm, and R. Brack-Werner. Molecular signature of astrocytes for gene delivery by the synthetic Adeno-associated viral vector rAAV9P1. Adv. Sci., 9:e2104979.
  13. L. Ernst, B. Steinfeld, U. Barayeu, T. Klintzsch, M. Kurth, D. Grimm, T.P. Dick, J.G. Rebelein, I.B. Bischofs, and F. Keppler. Methane formation driven by reactive ofygen species across all living organisms. Nature, 603:482-487.
  14. L. Maurer, J.E. Andari, K. Rapti, L. Spreyer, E. Steinmann, D. Grimm*, and L. Dao Thi. Induction of hepatits E virus anti-ORF3 antibodies from systemic administration. Viruses, 14:266. *equal corresponding and equal last author
  15. J. Becker, M.L. Stanifer, S.R. Leist, B. Stolp, O. Maiakovska, A. West, E. Wiedtke, K. Börner, A. Ghanem, I. Ambiel, L.V. Tse, O.T. Fackler, R.S. Baric, S. Boulant, and D. Grimm. Ex vivo and in vivo suppression of SARS-CoV-2 with combinatorial AAV-RNAi expression vectors. Mol. Ther., 30:2005-2023.

2021

  1. C.H. Hakim, S.R.P. Kumar, D.O. Perez-Lopez, N.B. Wasala, D. Zhang, Y. Yue, J. Teixeira, X. Pan, K. Zhang, E.D. Million, C.E. Nelson, S. Metzger, J. Han, J.A. Louderman, F. Schmidt, F. Feng, D. Grimm, B.F. Smith, G. Yao, N.N. Yang, C.A. Gersbach, S.-J. Chen, R.W. Herzog, and D. Duan. Cas9-specific immune responses compromise local and systemic AAV CRISPR therapy in multiple dystrophic canine models. Nat. Commun., 12:6769.
  2. C. Zhang, A. Freistaedter, C. Schmelas, M. Gunkel, V.L.D. Thi, and D. Grimm. An RNA interference/Adeno-associated virus vector-based combinatorial gene therapy approach against hepatitis E virus. Hepatol. Comm., 6:878-888.
  3. K. Rapti, and D. Grimm. Adeno-associated viruses (AAV) and host immunity – a race between the hare and the hedgehog. Front. Immunol., 12:753467.
  4. A. Michels, A.M. Frank, D.M. Günther, M. Mataei, K. Börner, D. Grimm, J. Hartmann, and C.J. Buchholz. Lentiviral and adeno-associated vectors efficiently transduce mouse T lymphocytes when targeted to murine CD8. Mol. Ther. Methods Clin. Dev., 23:334-347.
  5. L.P.M. Kremer, S. Cerrizuela, S. Dehler, T. Stiehl, J. Weinmann, H. Abendroth, S. Kleber, A. Laure, J. El Andari, S. Anders, A. Marciniak-Czochra, D. Grimm, and A. Martin-Villalba. In vivo high-throughput screening of novel adeno-associated viral capsids identifies variants for transduction of adult neural stem cells within the subventricular zone. Mol. Ther. Methods Clin. Dev., 23:33-50.
  6. M. Cheng, L. Dietz, Y. Gong, F. Eichler, J. Nammour, C. Ng, D. Grimm, and C. Maguire. Neutralizing antibody evasion and transduction with purified extracellular vesicle-enveloped AAV vectors. Hum. Gene Ther., 32:1457-1470.
  7. R. Luck, A. Karakatsani, B. Shah, G. Schermann, H. Adler, J. Kupke, N. Tisch, H.-W. Jeong, M. K. Müller, F. Hetsch, A. D’Errico, M. de Palma, E. Wiedtke, D. Grimm, A. Acker-Palmer, J. von Engelhardt., R.H. Adams, H.G. Augustin, and C.R. de Almodóvar. The angiopoietin-Tie2 pathway regulates Purkinje cell dendritic morphogenesis in a cell-autonomous manner. Cell Rep., 36:109522.
  8. N. Meng, and D. Grimm. Membrane-destabilizing ionizable phopsholipids: Novel components for organ-selective mRNA delivery and CRISPR-Cas gene editing. Signal Transduct. Target. Ther., 6:206.
  9. J.C. Yu, M. Mietzsch, A. Singh, A.J. Ybargollin, S. Kailasan, P. Chipman, N. Bhattacharya, J. Fakhiri, D. Grimm, A. Kapoor, I. Kucinskaite-Kodze, A. Zvirbliene, M. Söderlund-Venermo, R. McKenna, and M. Agbandje-McKenna. Characterization of the GBoV1 capsid and its antibody interactions. Viruses, 13:330.
  10. P. Michel-Gallardo*, K. Börner*, M.M. Pieler*, V. Sonntag-Buck, M. Obr, D. Bejarano, M.W. Wolff, H.-G. Kräusslich, U. Reichl, and D. Grimm. Single-use capture purification of adeno-associated viral gene transfer vectors by membrane-based steric exclusion chromatography. Hum. Gene Ther., 32:959-974. (*equal first)
  11. E. Murenu*, M. Pavlou*, L. Richter, K. Rapti, S. Just, J. Cehajic-Kapetanovic, N. Tafrishi, A. Hayes, R. Scholey, R. Lucas, H. Büning, D. Grimm, and S. Michalakis. A universal protocol for isolating retinal ON bipolar cells across species via fluorescence-activated cell sorting. Mol. Ther. Methods Clin. Dev., 20:587-600 (*equal first)
  12. J. Fakhiri, and D. Grimm. Best of most possible worlds: Hybrid gene therapy vectors based on parvoviruses and heterologous viruses. Mol. Ther., 29:3359-3382.
  13. F. Bubeck, and D. Grimm. “Hit-and-run” therapy averts macular degeneration. Nat. Biomed. Eng., 5:132-3.
  14. R. Medert, A. Jungmann, S. Hildebrand, M. Busch, D. Grimm, V. Flockerzi, O.J. Müller, P. Most, D. Schumacher, and M. Freichel. Development of an AAV9-RNAi mediated silencing strategy to abrogate TRPM4 expression in the adult heart. Pfluger’s Arch., 473:533-46.

2020

  1. M. Hoffmann, J. Mathony, J. Upmeier zu Belzen, Z. Hartevald, S. Aschenbrenner, C. Stengl, D. Grimm, B.E. Correira, R. Eils, and D. Niopek. Optogenetic control of Neisseria meningitidis Cas9 genome editing using an engineered, light-switchable anti-CRISPR protein. Nucleic Acids Res., 49:e29.
  2.  J. Fakhiri, L. Landegger, and D. Grimm. Breaking the sound barrier: Towards next-generation AAV vectors for gene therapy of hearing disorders. Hearing Res., 413:108092.
  3. J. El Andari, and D. Grimm. Production, processing and characterization of synthetic AAV gene therapy vectors. Biotech. J., 16:e2000025.
  4. J. Weinmann, S. Weis, J. Sippel, W. Tulalamba, A. Remes, J. El Andari, A.-K. Herrmann, Q.H. Pham, C. Borowski, S. Hille, T. Schöneberger, N. Frey, M. Lenter, T. VandenDriessche, O.J. Müller, M.K. Chuah, T. Lamla, and D. Grimm. Identification of a highly myotropic gene therapy vector by massively parallel in vivo stratification of AAV capsid variants on the DNA and RNA level. Nat. Commun., 11:5432.
  5. S. Klein, T.G. Müller, D. Khalid, V. Sonntag-Buck, A.-M. Heuser, B. Glass, M. Meurer, I. Morales, A. Schillak, A. Freistädter, I. Ambiel, S.L. Winter, L. Zimmermann, T. Naumoska, F. Bubeck, D. Kirrmaier, S. Ullrich, I.B. Miranda, S. Anders, D. Grimm, P. Schnitzler, M. Knop, H.-G. Kräusslich, V.L.D. Thi, K. Börner, and P. Chlanda. SARS-CoV-2 RNA extraction using magnetic beads for rapid large-scale testing by RT-qPCR and RT-LAMP. Viruses, 12:E863.
  6. E. Senis, L. Mosteiro, D. Grimm, and M. Abad. A versatile in vivo system to study Myc in cell reprogramming. Methods Mol. Biol., 2318:267-279.
  7. J. Fakhiri, K.-P. Linse, M. Mietzsch, M. Xu, M.A. Schneider, M. Meister, O. Schildgen, P. Schnitzler, M. Soderlund-Venermo, M. Agbandje-McKenna, and D. Grimm. Impact of natural or synthetic singletons in the capsid of human bocavirus 1 on particle infectivity and immunoreactivity. J. Virol., 94:e00170-20.
  8. J. Mathony*, Z. Harteveld*, C. Schmelas*, J. Upmeier zu Belzen, S. Aschenbrenner, W. Sun, M.D. Hoffmann, C. Stengl, A. Scheck, S. Georgeon, S. Rosset, Y. Wang, D. Grimm, R. Eils, B.E. Correira, and D. Niopek. Computational design of anti-CRISPR proteins with improved inhibition potency. Nat. Chem. Biol., 16:725-730. *equal first authors
  9. K. Börner*, E. Kienle*, L.-Y. Huang, J. Weinmann, A. Sacher, P. Bayer, C. Stüllein, J. Fakhiri, L. Zimmermann, A. Westhaus, J. Beneke, N. Beil, E. Wiedtke, C. Schmelas, D. Miltner, A. Rau, H. Erfle, H.-G. Kräusslich, M. Müller, M. Agbandje-McKenna, and D. Grimm. Pre-arrayed pan-AAV peptide display libraries for rapid single-round screening. Mol. Ther., 28:1016-1032. *equal first authors
  10. T. Michler, A.D. Kosinska, J. Festag, T. Bunse, J. Su, M. Ringelhan, H. Imhof, D. Grimm, K. Steiger, C. Mogler, M. Heikenwalder, M.-L. Michel, C.A. Guzman, S. Milstein, L. Sepp-Lorenzino, P. Knolle, and U. Protzer. Knockdown of virus antigen expression increases therapeutic vaccine efficacy in high-titer HBV carrier mice. Gastroenterology, 158:1762-1775.
  11. S. Krooss, Z. Dai, F. Schmidt, A. Rovai, J. Fakhiri, A. Dhingra, Q. Yuan, T. Yang, A. Balakrishnan, L. Steinbrück, S. Srivaratharajan, M.P. Manns, A. Schambach, D. Grimm, J. Bohne, A.D. Sharma, H. Büning, and M. Ott. Ex/in vivo gene editing in hepatocytes using “all-in-one” CRISPR-AAV vectors with a self-linearizing repair template. iScience, 23:100764.

2019

  1. F. Hentzschel, V. Mitesser, S. Fraschka, D. Krzikalla, E. Herrera-Carrillo, B. Berkhout, R. Bartfai, A.-K. Mueller, and D. Grimm. Gene knockdown in malaria parasites via non-canonical RNAi. Nucleic Acids Res., doi: 10.1093/nar/gkz927.
  2. A.M. Eichhoff, K. Börner, B. Albrecht, W. Schäfer, N. Baum, F. Haag, J. Körbelin, M. Trepel, I. Braren, D. Grimm, S. Adriouch, and F. Koch-Nolte. Nanobody-enhanced targeting of AAV gene therapy vectors. Mol. Ther. – Meth. & Clin. Dev., 15:211-220.
  3. W. Tulalamba*, J. Weinmann*, Q. Pham*, J. El Andari, T. VandenDriessche, M. Chuah, and D. Grimm. Distinct transduction of muscle tissue in mice after systemic delivery of AAVpo1 vectors. Gene Ther., 27:170-179. *equal first authorship
  4. C. Domenger, and D. Grimm. Next-generation AAV vectors – don’t judge a virus (only) by its cover. Hum. Mol. Genet., 28:R3-R14.
  5. M. Hoffmann, S. Aschenbrenner, S. Grosse, K. Rapti, C. Domenger, J. Fakhiri, M. Mastel, K. Börner, R. Eils, D. Grimm, and D. Niopek. Cell-specific CRISPR-Cas9 activation by microRNA-dependent expression of anti-CRISPR proteins. Nucleic Acids Res., 47:e75.
  6. J. Tabatabai, J. Fakhiri, J. Meyburg, K.-P. Linse, M. Söderlund-Vernermo, D. Grimm, and P. Schnitzler. Severe human bocavirus 1 respiratory tract infection in an immunodeficient child with fatal outcome. Pediatr. Infect. Dis. J., 38:e219-e222.
  7. J. Fakhiri, M. Schneider, J. Puschhof, M. Stanifer, V. Schildgen, S. Holderbach, Y. Voss, J. El Andari, O. Schildgen, S. Boulant, M. Meister, H. Clevers, Z. Yan, J. Qiu, and D. Grimm. Novel chimeric gene therapy vectors based on Adeno-associated virus (AAV) and four different mammalian bocaviruses (BoV). Mol. Ther. – Meth. & Clin. Dev., 12:202-222.
  8. J. Fakhiri, M. Nickl, and D. Grimm. Rapid and simple screening of CRISPR g(uide)RNAs in cultured cells using Adeno-associated viral (AAV) vectors. Methods Mol. Biol., 1961:111-126.
  9. S. Fanucchi, E. Fok, E. Dalla, Y. Shibayama, K. Börner, E. Chang, S. Stoychev, M. Imakaev, D. Grimm, K. Wang, G. Li, K. Sung, and M. Mhlanga. Immune genes are primed for robust transcription by proximal lncRNAs located in nuclear compartments. Nat. Genet., 51:138-150.

2018

  1. A.-K. Herrmann, C. Bender, E. Kienle, S. Grosse, J. El Andari, J. Botta, N. Schürmann, E. Wiedtke, D. Niopek, and D. Grimm. A robust and all-inclusive pipeline for shuffling of Adeno-associated viruses (AAV). ACS Synth. Biol., doi: 10.1021/acssynbio.8b00373.
  2. G. Wolff, A.E. Taranko, I. Meln, J. Weinmann, T. Sijmonsma, S. Lerch, D. Heide, A.T. Billeter, D. Tews, D. Krunic, P. Fischer-Posovszky, B.P. Müller-Stich, S. Herzig, D. Grimm, M. Heikenwälder, W.W. Kao, and A. Vegiopoulos. Diet-dependent function of the extracellular matrix proteoglycan Lumican in obesity and glucose homeostasis. Mol. Metabol., 19:97-106.
  3. F. Bubeck, M. Hoffmann, Z. Harteveld, S. Aschenbrenner, A. Bietz, M. Waldhauer, K. Börner, J. Fakhiri, C. Schmelas, L. Dietz, D. Grimm, B. Correia, R. Eils, and D. Niopek. Engineered anti-CRISPR proteins for optogenetic control of CRISPR/Cas9. Nat. Methods, 15:924-7.
  4. A.-K. Herrmann, S. Große, K. Börner, C. Krämer, E. Wiedtke, M. Gunkel, and D. Grimm. Impact of the assembly-activating protein (AAP) on molecular evolution of synthetic Adeno-associated virus (AAV) capsids. Hum. Gene Ther., 30:21-35.
  5. D.M.C. dos Santos, J. Eilers, A.S. Vizcaino, E. Orlova, M. Zimmermann, M. Stanulla, M. Schrappe, K. Börner, D. Grimm, M.U. Muckenthaler, A.E. Kulozik, and J.B. Kunz. MAP3K7 is recurrently deleted in pediatric T-lymphoblastic leukemia and affects cell proliferation independently of NF-KB. BMC Cancer, 18:663.
  6. E. Senís, L. Mosteiro, S. Wilkening, E. Wiedtke, A. Nowrouzi, S. Afzal, R. Fronza, H. Landerer, M. Abad, D. Niopek, M. Schmidt, M. Serrano, and D. Grimm. AAV vector-mediated in vivo reprogramming into pluripotency. Nat. Commun., 9:2651.
  7. A.-K. Herrmann, and D. Grimm. High-throughput dissection of AAV-host interactions: The fast and the curious. J. Mol. Biol., 430:2626-2640.
  8. C. Schmelas, and D. Grimm. Split Cas9, not hairs – advancing the therapeutic index of CRISPR technology. Biotechnol. J., 13:e1700432.
  9. W.P.-K. Lou, A. Mateos, M. Koch, S. Klussmann, C. Yang, N. Lu, S. Kumar, S. Limpert, M. Göpferich, M. Zschaetzsch, C. Sliwinski, M. Kenzelmann, M. Seedorf, C. Maillo, E. Senis, D. Grimm, R. Puttagunta, R. Mendez, K. Liu, B. Hassan, and A. Martin-Villalba. Regulation of adult CNS axonal regeneration by the post-transcriptional regulator Cbep1. Frontiers Mol. Neurosci., 10:445.
  10. C. Kunze, K. Börner, E. Kienle, T. Orschmann, E. Rusha, M. Schneider, M. Radivojkov-Blagojevic, M. Drukker, S. Desbordes, D. Grimm, and R. Brack-Werner. Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia, 66:413-427.

2017

  1. L. Amoasii, C. Long, H. Li, A.A. Mireault, J.M. Shelton, E. Sanchez-Ortiz, J.R. McAnally, S. Bhattacharyya, F. Schmidt, D. Grimm, S.D. Hauschka, R. Bassel-Duby, and E. Olson. Single cut genome editing restores dystrophin expression in a new mouse model of muscular dystrophy. Sci. Transl. Med., doi: 10.1126/scitranslmed.aan8081.
  2. D. Grimm, and H. Büning. Small but increasingly mighty – Latest advances in AAV vector research, design and evolution. Hum. Gene Ther., 28:1075-1086.
  3. S. Grosse, M. Penauld-Budloo, A.-K. Herrmann, K. Börner, J. Fakhiri, V. Laketa, C. Krämer, E. Wiedtke, M. Gunkel, L. Menard, E. Ayuso, and D. Grimm. Relevance of assembly-activating protein for Adeno-associated virus vector production and capsid protein stability in mammalian and insect cells. J. Virol., doi: 10.1128/JVI.01198-17.
  4. J. Weinmann, and D. Grimm. Next-generation AAV vectors for clinical use: An ever accelerating race. Virus Genes, 53:707-713.
  5. K. Pervorlakari, M.L. Stanifer, S. Münchau, L.A. Renn, D. Albrecht, S. Kurzhals, E. Senís, D. Grimm, J. Schröder-Braunstein, R.L. Rabin, and S. Boulant. Type I and type III interferons display different dependency on MPAKs to mount an antiviral state in the human gut. Frontiers Immunol., 8:459.
  6. F.A. Lempp, E. Wiedtke, B. Qu, P. Roques, I. Chemin, F.W.R. Voudran, R.L. Grand, D. Grimm, and S. Urban. Sodium taurocholate cotransporting polypeptide is the limiting host factor of Hepatitis B Virus infection in macaque and pig hepatocytes. Hepatology, 66:703-716.
  7. C.S. e Cunha, B. Nyboer, K. Heiss, M. Sanchez-Vaz, D. Fontinha, E. Wiedtke, D. Grimm, J.M. Przyborski, M.M. Mota, M. Prudencio, and A.-K. Mueller. P. berghei EXP-1 interacts with host apolipoprotein H during Plasmodium liver stage development. PNAS, 114:E1138-47.
  8. E. Senís, S. Mockenhaupt, D. Rupp, T. Bauer, N. Paramasivam, B. Knapp, J. Gronych, S. Grosse, M.P. Windisch, F. Schmidt, F.J. Theis, R. Eils, P. Lichter, M. Schlesner, R. Bartenschlager, and D. Grimm. TALEN/CRISPR-mediated engineering of a promoterless anti-viral RNAi hairpin into an endogenous miRNA locus. Nucleic Acids Res., 45:e3.

2016

  1. T. Michler, S. Grosse, S. Mockenhaupt, N. Röder, F. Stückler, B. Knapp, C. Ko, M. Heikenwälder, U. Protzer, and D. Grimm. Blocking sense strand activity improves potency, safety and specificity of anti-hepatitis B virus short hairpin RNA. EMBO Mol. Med., 8:1082-1098.
  2. D. Ebrahimi-Fakhari, L. Wahlster, F. Bartz, J. Werenbeck-Ueding, M. Praggastis, J. Zhang, B. Joggerst-Thomalla, S. Theiss, D. Grimm, D. Ory, and H. Runz. Reduction of TMEM97 increases NPC1 protein levels and restores cholesterol trafficking in Niemann-Pick type C1 disease cells. Hum. Mol. Gen., 25:3588-3599.
  3. F.M. Pujol, V. Laketa, F. Schmidt, M. Mukenhirn, B. Müller, S. Boulant, D. Grimm, O.T. Keppler, and O.T. Fackler. HIV-1 Vpu antagonizes CD317/tetherin by adaptor protein-1-mediated exclusion from the virus assembly sites. J. Virol., 90:6709-6723.
  4. M. Rezvani, R. Espanol-Suner, Y. Malato, L. Dumont, A.A. Grimm, E. Kienle, J.G. Bindman, E. Wiedtke, B.Y. Hsu, S.J. Naqvi, R.F. Schwabe, C.U. Corvera, D. Grimm, and H. Willenbring. In vivo reprogramming of myofibroblasts into hepatocytes as a therapeutic strategy for liver fibrosis. Cell Stem Cell, 18:809-816.
  5. F. Hentzschel*, A.-K. Herrmann*, A.-K. Mueller, and D. Grimm. Plasmodium meets AAV – the (un)likely marriage of parasitology and virology, and how to make the match. FEBS Letters, 590:2027-2045. (*equal first)
  6. C. Liesche, L. Venkatraman, S. Aschenbrenner, S. Grosse, D. Grimm, R. Eils, and J. Beaudouin. Death receptor-based enrichment of Cas9-expressing cells. BMC Biotechnol., 16:17.

2015

  1. M. Singer, J. Marshall, K. Heiss, G. Mair, D. Grimm, A.-K. Mueller, and F. Frischknecht. Zinc finger nuclease-induced double-strand breaks lead to attenuated malaria parasites lacking hundreds of genes and reveals rare microhomology-mediated end joining. Genome Biol., 16:249.
  2. D. Grimm, and S. Zolotukhin. E pluribus unum: Fifty years of research, millions of viruses, and one goal – tailored acceleration of AAV evolution. Mol. Ther., 23:1819-31.
  3. S. Mockenhaupt, S. Grosse, D. Rupp, R. Bartenschlager, and D. Grimm. Alleviation of off-target effects from vector-encoded shRNA via co-delivered RNA decoys. PNAS, 112:E4007-16.
  4. S. Mueller, J. Huard, K. Waldow, X. Huang, L.A. D’Alessandro, S. Bohl, K. Börner, D. Grimm, S. Klamt, U. Klingmüller, and M. Schilling. T160-phosphorylated CDK2 defines threshold for HGF-dependent proliferation in primary hepatocytes. Mol. Sys. Biol., 11:795.
  5. F. Schmidt, and D. Grimm. CRISPR genome engineering and viral gene delivery: A case of mutual attraction. Biotechnol. J., 10:258-72.

2014

  1. S. Uhrig-Schmidt, M. Geiger, G. Luippold, G. Birk, D. Mennerich, H. Neubauer, D. Grimm, C. Wolfrum, and S. Kreuz. Gene delivery to adipose tissue using transcriptionally targeted rAAV8 vectors. PLoS ONE, 9:e116288.
  2. E. Carnero, M. Barriocanal, V. Segura, E. Guruceaga, C. Prior, K. Börner, D. Grimm, and P. Fortes. Type I interferon regulates the expression of long noncoding RNAs. Frontiers Immunol., 5:548.
  3. F. Hentzschel*, C. Hammerschmidt-Kamper*, K. Börner*, K. Heiss*, B. Knapp, J. M. Sattler, L. Kaderali, M. Castoldi, J. G. Bindman, Y. Malato, H. Willenbring, A.-K. Mueller, and D. Grimm. AAV8-mediated in vivo overexpression of miR-155 enhances the protective capacity of genetically-attenuated malarial parasites. Mol. Ther., 22:2130-41. (* equal first)
  4. E. Senís*, C. Fatouros*, S. Grosse*, E. Wiedtke, D. Niopek, A.-K. Mueller, K. Börner, and D. Grimm. An adeno-associated viral (AAV) vector toolbox for CRISPR/Cas9-mediated genome engineering. Biotechnol J., 9:1402-12. (* equal first)
  5. M. Hörner, B. Kaufmann, G. Cotugno, E. Wiedtke, H. Büning, D. Grimm, and W. Weber. A chemical switch for controlling viral infectivity. Chem. Comm., 50:10319-22.
  6. E. Senís, and D. Grimm. From Mice to Men: Towards the Clinical Translation of MicroRNA Technologies for Somatic Cell Reprogramming. In: Applied RNAi: From Fundamental Research To Therapeutic Applications (Caister Academic Press; Eds. P. Arbuthnot & M. Weinberg). p 51-77.

2013

  1. N. Schürmann, L. G. Trabuco, C. Bender, R. B. Russell, and D. Grimm. Molecular dissection of human Argonaute proteins using DNA family shuffling. Nat. Struct. & Mol. Biol. 20:818-26.
  2. K. Börner, D. Niopek, G. Cotugno, M. Kaldenbach, T. Pankert, J. Willemsen, X. Zhang, N. Schürmann, S. Mockenhaupt, A. Serva, M.S. Hiet, E. Wiedtke, M. Castoldi, V. Starkuviene, H. Erfle, D.F. Gilbert, R. Bartenschlager, M. Boutros, M. Binder, K. Streetz, H.-G. Kräusslich, and D. Grimm. Robust RNAi enhancement via human Argonaute-2 overexpression from plasmids, viral vectors and cell lines. Nucleic Acids Res. 41:e199.
  3. S. Heymans, M.F. Corsten, W. Verhesen, P. Carai, R.E. van Leeuwen, K. Custers, T. Peters, M. Hazebroek, L. Stöger, E. Wijnands, B.J. Janssen, E.E. Creemers, Y.M. Pinto, D. Grimm, N. Schürmann, E. Vigorito, T. Thum, F. Stassen, X. Yin, M. Mayr, L.J. de Windt, E. Lutgens, K. Wouters, M.P. de Winther, S. Zacchigna, M. Giacca, M. van Bilsen, A.P. Papageorgiou, and B. Schroen. Macrophage MicroRNA-155 promotes cardiac hypertrophy and failure. Circulation 128:1420-32.

2012

  1. D. Grimm. All for one, one for all: New combinatorial RNAi therapies to defeat Hepatitis C virus evolution. Mol. Ther. 20:1661-3.
  2. E. Kienle, E. Senís, K. Börner, D. Niopek, S. Grosse, E. Wiedtke, and D. Grimm. Engineering and evolution of synthetic Adeno-associated virus (AAV) gene therapy vectors via DNA family shuffling. J. Vis. Exp. 2: 3819.
  3. D. Grimm, T. Dalmay, and R.P. van Rij. Everybody wins! Poland hosts thrilling competitions of viruses, RNAi and football teams. EMBO Rep. 13:874-6.

2011

  1. P. Valdmanis, S. Gu, N. Schürmann, P. Sethupathy, D. Grimm, and M.A. Kay. Expression determinants of mammalian Argonaute proteins in mediated gene silencing. Nucleic Acids Res. 40: 3704-13.
  2. D. Grimm. The dose can make the poison: lessons learned from adverse in vivo toxicities caused by RNAi overexpression. Silence 2:8.
  3. S. Mockenhaupt, K. Börner, and D. Grimm. Perturbation of the cellular RNAi machinery in disease and therapy: Lessons learned and avenues paved. DGZ Cell News 2:8-16.
  4. D. Niopek, R. Berrens, S. Mockenhaupt, M.D. Lewis, A.K. Mueller, and D. Grimm. To go, or not to go, that is the question – six personal reflections on how geographic mobility may affect your career and life. Bioessays 33:728-31.
  5. S. Mockenhaupt, and D. Grimm. Adeno-assoziierte Viren für effizientes Gene Targeting in humanen Zellen. BIOspektrum 05/11:533-6.
  6. Y. Malato, S. Nagvi, N. Schürmann, R. Ng, B. Wang, J. Zape, M. Kay, D. Grimm, and H. Willenbring. Fate-tracing of mature hepatocytes in mouse liver homeostasis and regeneration. J. Clin. Invest. 121:4850-60.
  7. S. Mockenhaupt, N. Schürmann, and D. Grimm. When cellular networks run out of control: Global dysregulations of the RNAi machinery in human pathology and therapy. Prog. Mol. Biol. Transl. Sci. 2011 102:165-242.
  8. S. Gu, L. Jin, F. Zhang, Y. Huang, D. Grimm, J. Rossi, and M.A. Kay. The thermodynamic stability of small hairpin RNAs highly influences the loading process of different mammalian Argonautes. PNAS 108:9208-13.

2010

  1. D. Grimm, L. Wang, J.S. Lee, N. Schürmann, S. Gu, K. Börner, T.A. Storm, and M.A. Kay. Argonaute proteins are key determinants of RNAi efficacy, toxicity, and persistence in the adult mouse liver. J. Clin. Invest. 120:3106-19.
  2. S. Beer, D.I. Bellovin, J.S. Lee, K. Komatsubara, L.S. Wang, S. Koh, K. Börner, T.A. Storm, C.R. Davis, M.A. Kay, D.W. Felsher, and D. Grimm. Low-level shRNA cytotoxicity can contribute to MYC-induced hepatocellular carcinoma in mice. Mol. Ther. 18:161-70.
  3. K. Börner, and D. Grimm. Use of small RNAs for therapeutic gene silencing: risk versus benefit. Drug Disc. Today: Technol. 7:e51-e57.
  4. P. Parameswaran, E. Sklan, T. Burgon, M.A. Samuel, C. Wilkins, R. Lu, K.M. Ansel, V. Heissmeyer, S. Einav, W. Jackson, T. Doukas, S. Paranjape, C. Polacek, F.B. dos Santos, R. Jalili, F. Babrzadeh, B. Gharizadeh, D. Grimm, M. Kay, P. Sarnow, M. Ronaghi, S.-W. Ding, E. Harris, M. Chow, M.S. Diamond, K. Kirkegaard, J. Glenn, and A. Fire. 6 RNA Viruses & 41 hosts: vsRNAs and viral modulation of small RNA repertoires in vertebrate and invertebrate systems. PLoS Pathogens, 12: e1000764.
  5. D. Grimm. Small Silencing RNAs and Gene Therapy. In: Encylopedia of Life Sciences, John Wiley & Sons, Ltd: Chichester www.els.net [DOI: 10.1002/9780470015902.a0022396]

2009

  1. D. Grimm. Small silencing RNAs: State-of-the-art. Adv. Drug Del. Rev. 61:672-703.
  2. D. Grimm. Asymmetry in siRNA design. Gene Ther. 16:827-29.
  3. D. Grimm. Klein aber ungemein fein: Winzige rekombinante Viren als Träger für RNAi-Moleküle. Bioforum 5:21-23 & 6:12-14.

2008

  1. J. Giering, D. Grimm, T.A. Storm, and M.A. Kay. Expression of shRNA from a tissue-specific pol II promoter is an effective and safe RNAi therapeutic. Mol. Ther. 16:1630-6 .
  2. D. Grimm, J.S. Lee, L. Wang, T. Desai, B. Akache, T.A. Storm, and M.A. Kay. In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and re-targeting of adeno-associated viruses. J. Virol. 82:5887-911. (Faculty of 1000 score of 9.0)
  3. H. Doege, D. Grimm, A. Falcon, B. Tsang, T.A. Storm, H. Xu, A.M. Ortegon, M. Kazantzis, M.A. Kay, and A. Stahl. Silencing of hepatic fatty acid transporter protein 5 in vivo reverses diet-induced non-alcoholic fatty liver disease and improves hyperglycemia. J. Biol. Chem. 283:22186-92.
  4. K. Streetz, R. Doyonnas, D. Grimm, D.D. Jenkins, S. Fuess, S. Perryman, J. Lin, C. Trautwein, J. Shizuru, H. Blau, K.G. Sylvester, and M.A. Kay. Successful engraftment of transplanted allogeneic hepatocytes is mediated by bone marrow transplantation and in vivo CD4(+) cell selection. Hepatology, 47:706-18.

2007

  1. D. Grimm, and M.A. Kay. Therapeutic RNAi applications: Is mRNA targeting finally ready for prime-time ? J. Clin. Invest. 117:3633-41.
  2. D.M. Paskowitz, K.P. Greenberg, D. Yasumura, D. Grimm, J.L. Duncan, M.A. Kay, M.M. LaVail, J.G. Flannery, and D. Vollrath. Rapid and stable knockdown of an endogenous gene in retinal pigment epithelium. Hum. Gene Ther. 18: 871-80.
  3. B. Akache, D. Grimm, X. Shen, S. Fuess, S.R. Yant, D.S. Glazer, J. Park, and M.A. Kay. A two-hybrid screen identifies cathepsins B and L as potential uncoating factors for adeno-associated virus 2 and 8. Mol. Ther. 15:330-9.
  4. D. Grimm, and M.A. Kay. RNAi and gene therapy: A mutual attraction. Hematology Am. Soc. Hematol. Educ. Program 2007, 2007:473-81.
  5. D. Grimm, and M.A. Kay.Combinatorial RNAi: A winning strategy for the race against evolving targets ? Mol. Ther., 15:878-88.

2006

  1. D. Grimm, K.S. Streetz, C.L. Jopling, T.A. Storm, K. Pandey, C.R. Davis, P. Marion, F. Salazar, and M.A. Kay. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441:537-41. (Faculty of 1000 score of 6.4)
  2. D. Grimm, and M.A. Kay. Therapeutic short hairpin RNA expression in the liver: viral targets and vectors. Gene Ther. 13:563-75.
  3. D. Grimm, K. Pandey, H. Nakai, T.A. Storm, and M.A. Kay. Liver transduction with recombinant Adeno-associated virus is primarily restricted by viral serotype, not vector genotype. J. Virol. 80:429-36.
  4. B. Akache, D. Grimm, K. Pandey, S. Yant, H. Xu, and M.A. Kay. The 37/67-kildodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9. J. Virol. 80:9831-6.
  5. O.J. Müller, B. Leuchs, S.T. Pleger, D. Grimm, W.M. Franz, H.A. Katus, and J.A. Kleinschmidt. Improved cardiac gene transfer by transcriptional and transductional targeting of adeno-associated viral vectors. Cardiovasc. Res.70:70-8 .

2005

  1. E. Riu, D. Grimm, Z. Huang, and M.A. Kay. Increased maintenance and persistence of transgenes by excision of expression cassettes from plasmid sequences in vivo. Hum. Gene Ther. 16:558-70.
  2. D. Grimm, K. Pandey, and M.A. Kay. Adeno-associated virus vectors for short hairpin RNA expression. Methods Enzymol. 392:381-405.

2004

  1. D. Grimm, and M.A. Kay. From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy. Curr. Gene Ther. 3:281-304.

2003

  1. D. Grimm, S. Zhou, H. Nakai, C.E. Thomas, T.A. Storm, S. Fuess, T. Matsushita, J. Allen, R. Surosky, M. Lochrie, L. Meuse, A. McClelland, P. Colosi, and M.A. Kay. Pre-clinical in vivo evaluation of pseudotyped adeno-associated virus (AAV) vectors for liver gene therapy. Blood 102:2412-9.
  2. D. Grimm, M.A. Kay, and J.A. Kleinschmidt. Helper virus-free, optically-controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6. Mol. Ther. 7:839-50.

2002

  1. D. Grimm. (Update 2008). AAV. In: Encyclopedic Reference of Cancer. Springer Verlag, Heidelberg. (Ed. M. Schwab). 5-10.
  2. N. Salome, and D. Grimm. Gentherapie mit Parvoviren ? In: Krebsforschung heute. Berichte aus dem Deutschen Krebsforschungszentrum. Steinkopff Darmstadt. (Ed. H. Stamatiadis-Smidt). 168-73.
  3. D. Grimm. Production methods for gene transfer vectors based on adeno-associated virus serotypes. Methods 28:146-57.
  4. U.P. Rohr, R. Kronenwett, D. Grimm, J. Kleinschmidt, and R. Haas. Primary human cells differ in their susceptibility to rAAV-2-mediated gene transfer and duration of reporter gene expression. J. Virol. Meth. 105:265-75.

2001

  1. J.A. King, R. Dubielzig, D. Grimm, and J.A. Kleinschmidt. DNA helicase-mediated packaging of adeno-associated virus type 2 genomes into preformed capsids. EMBO J. 20:3282-91.
  2. S. Jiang, A. Altmann, D. Grimm, J.A. Kleinschmidt, T. Schilling, C. Germann, and U. Haberkorn. Tissue-specific gene expression in medullary thyroid carcinoma cells employing calcitonin regulatory elements and AAV vectors. Cancer Gene Ther. 8:469-72.
  3. J. Smith, R. Herrero, K. Erles, D. Grimm, N. Munoz, F.X. Bosch, L. Tafur, K.V. Shah, and J.R. Schlehofer. Adeno-associated virus seropositivity and HPV-induced cervical cancer in Spain and Colombia. Int. J. Cancer  94:520-6.

2000

  1. D. Kunke, D. Grimm, S. Denger, J. Kreuzer, H. Delius, D. Komitowski, and J.A. Kleinschmidt. Preclinical study on gene therapy of cervical carcinoma using adeno-associated virus vectors. Cancer Gene Ther. 7:766-77.
  2. D. Grimm. Adeno-associated virus (AAV) serotypes as vectors for human gene therapy. In: Research advances in virology. Global Research Network, India. (Ed. R. M. Mohan). 91-114.
  3. D. Grimm, and J.A. Kleinschmidt. Strategies for production of adeno-associated virus vectors. In: Viral Vectors: Basic Science & Gene Therapy. Eaton Publishing, Natick, MA. (Eds. A. Cid-Arregui and A. Garcia). 27-57.

1999

  1. D. Grimm, and J.A. Kleinschmidt. Progress in adeno-associated virus type 2 vector production: promises and prospects for clinical use. Hum. Gene Ther.10:2445-50 .
  2. D. Grimm, A. Kern, M. Pawlita, F. Ferrari, R. Samulski, and J.A. Kleinschmidt. Titration of AAV-2 particles via a novel capsid ELISA: packaging of genomes can limit production of recombinant AAV-2. Gene Ther. 6:1322-30.
  3. A. Hörster, B. Teichmann, R. Hormes, D. Grimm, J. Kleinschmidt, and G. Sczakiel. Recombinant AAV-2 harboring gfp-antisense/ribozyme fusion sequences monitor transduction, gene expression, and show anti-HIV-1 efficacy. Gene Ther. 6:1231-8.
  4. W.T. Hermens, O. ter Brake, P.A. Dijkhuizen, M.A. Sonnemans, D. Grimm, J.A. Kleinschmidt, and J. Verhaagen. Purification of recombinant adeno-associated virus by iodixanol gradient ultracentrifugation allows rapid and reproducible preparation of vector stocks for gene transfer in the nervous system. Hum. Gene Ther. 10:1885-91.

1998

  1. D. Grimm, A. Kern, K. Rittner, and J.A. Kleinschmidt. Novel tools for production and purification of recombinant adeno-associated virus vectors. Hum. Gene Ther.9:2745-60.

1997

  1. A. Wistuba, A. Kern, S. Weger, D. Grimm, and J.A. Kleinschmidt. Subcellular compartmentalization of adeno-associated virus type 2 assembly. J. Virol.71:1341-52 .
  2. S. Weger, A. Wistuba, D. Grimm, and J.A. Kleinschmidt. Control of adeno-associated virus type 2 cap gene expression: relative influence of helper virus, terminal repeats, and rep proteins. J. Virol. 71:8437-47.